DE60036871D1 - Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheiten - Google Patents

Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheiten

Info

Publication number
DE60036871D1
DE60036871D1 DE60036871T DE60036871T DE60036871D1 DE 60036871 D1 DE60036871 D1 DE 60036871D1 DE 60036871 T DE60036871 T DE 60036871T DE 60036871 T DE60036871 T DE 60036871T DE 60036871 D1 DE60036871 D1 DE 60036871D1
Authority
DE
Germany
Prior art keywords
sibo
disclosed
diagnosis
fibromyalgia
crohn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036871T
Other languages
English (en)
Other versions
DE60036871T2 (de
Inventor
Henry C Lin
Mark Pimental
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23475487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60036871(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of DE60036871D1 publication Critical patent/DE60036871D1/de
Application granted granted Critical
Publication of DE60036871T2 publication Critical patent/DE60036871T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L67/00—Network arrangements or protocols for supporting network services or applications
    • H04L67/01—Protocols
    • H04L67/12—Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks
    • H04L67/125—Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks involving control of end-device applications over a network
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L69/00—Network arrangements, protocols or services independent of the application payload and not provided for in the other groups of this subclass
    • H04L69/08—Protocols for interworking; Protocol conversion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
DE60036871T 1999-08-11 2000-08-11 Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheiten Expired - Lifetime DE60036871T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US374142 1999-08-11
US09/374,142 US6861053B1 (en) 1999-08-11 1999-08-11 Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
PCT/US2000/022030 WO2001011077A2 (en) 1999-08-11 2000-08-11 Methods of diagnosing or treating irritable bowel syndrome and other disorders

Publications (2)

Publication Number Publication Date
DE60036871D1 true DE60036871D1 (de) 2007-12-06
DE60036871T2 DE60036871T2 (de) 2008-09-18

Family

ID=23475487

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036871T Expired - Lifetime DE60036871T2 (de) 1999-08-11 2000-08-11 Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheiten

Country Status (10)

Country Link
US (9) US6861053B1 (de)
EP (5) EP1811303B1 (de)
AT (2) ATE514946T1 (de)
AU (1) AU6538300A (de)
CY (1) CY1114368T1 (de)
DE (1) DE60036871T2 (de)
DK (2) DK2256498T3 (de)
ES (3) ES2366235T3 (de)
PT (2) PT1811303E (de)
WO (1) WO2001011077A2 (de)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348986A (en) * 1990-11-19 1994-09-20 Loctite Corporation Photocurable silicone composition, and method of making same
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
JP2003523330A (ja) * 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US20050054942A1 (en) * 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2444637A1 (en) * 2001-01-16 2002-07-18 Ramot University Authority For Applied Research & Industrial Development Ltd. Hybrid peptides for treatment of bacteremia and septicemia
GB2371983A (en) * 2001-02-12 2002-08-14 Reckitt & Colmann Prod Ltd Compositions to treat irritable bowel syndrome
WO2009085968A1 (en) * 2007-12-19 2009-07-09 Great Lakes Biosciences, Llc Brain-related chronic pain disorder diagnosis and assessment method
WO2003100023A2 (en) * 2002-05-20 2003-12-04 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
EP1511502A2 (de) * 2002-06-13 2005-03-09 Alimentary Health Limited Probiotische therapien mit lactobazillus reuteri
EP1384483A1 (de) * 2002-07-23 2004-01-28 Nestec S.A. Probiotische Mikroorganismen zur Behandlung von Colon Irritabile durch die Verbesserung der neuromuskulären Darmfunktion
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
ATE395596T1 (de) * 2002-10-25 2008-05-15 Techlab Inc Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) * 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
JP2007520495A (ja) * 2004-02-06 2007-07-26 ボロディー トーマス ユリウス 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法
US7125963B2 (en) 2004-03-03 2006-10-24 En N Tech Inc Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
ITMI20041295A1 (it) * 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
EP1784381A1 (de) * 2004-08-26 2007-05-16 Neurosearch A/S Neue substituierte aryloxyalkylamine und deren verwendung als monoamin neurotransmitter wiederaufnahmehemmer
JP2008511593A (ja) * 2004-09-03 2008-04-17 セーホーエル．ハンセン アクティーゼルスカブ 受容体リガンドを含む発酵乳又は植物性タンパク質及びその使用
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20060078546A1 (en) * 2004-10-07 2006-04-13 Anders Zachrisson Use of lactic acid bacteria to reduce sick time
EP1698630B1 (de) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. Neue polymorphe Formen von Rifaximin, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
WO2006102536A2 (en) * 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8246946B2 (en) * 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
US7868139B2 (en) * 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
EP2139462B1 (de) * 2007-03-30 2014-01-22 Amgen Inc. Calcimimetische verbindungen zur verwendung bei der behandlung von darmerkrankungen
EP2152318A4 (de) * 2007-06-01 2011-12-07 Abbott Biotech Ltd Anwendungen und zusammensetzungen zur behandlung von schuppenflechten und morbus crohn
US8261327B2 (en) * 2007-07-12 2012-09-04 Wayport, Inc. Device-specific authorization at distributed locations
WO2009055769A1 (en) 2007-10-25 2009-04-30 Phytoceutica, Inc. Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
FI20080321A0 (fi) * 2008-04-25 2008-04-25 Eino Elias Hakalehto Menetelmä suoliston bakteeritasapainon ylläpitämiseksi
EP2294012B1 (de) * 2008-05-07 2014-07-09 Salix Pharmaceuticals, Ltd. Verabreichung eines Darmreinigers und eines Antibiotikums zur Behandlung von Darmerkrankung
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (de) * 2008-07-01 2019-06-12 Curemark, Llc Verfahren und zusammensetzungen zur behandlung von symptomen von neurologischen und geistesstörungen
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
ES2496190T3 (es) 2008-09-26 2014-09-18 Aska Pharmaceutical Co., Ltd. Agente profiláctico y/o terapéutico para trastornos gastrointestinales funcionales
MX2011003548A (es) 2008-10-02 2011-06-21 Salix Pharmaceuticals Ltd Metodos para tratar la encefalopatia hepatica.
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
WO2010062959A1 (en) * 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
EP3064217B1 (de) 2009-01-06 2018-04-18 Galenagen, LLC Zusammensetzungen enhaltend protease, amylase and lipase zur verwendung in der behandlung von staphylococcus aureus-infektionen
MX2011008354A (es) * 2009-02-11 2011-09-06 Cedars Sinai Medical Center Terapia antibiotica para reducir la probabilidad de desarrollar el sindrome del intestino irritable post-infeccioso.
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
DK2442647T3 (en) 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivatives thereof, and the uses of these
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
KR20120062897A (ko) * 2009-09-13 2012-06-14 샐릭스 파마슈티컬스 리미티드 과민성 장 증후군(ｉｂｓ)의 치료방법
EP3260126A1 (de) * 2009-10-09 2017-12-27 Prothera, Inc. Zusammensetzungen und verfahren mit pediokokken zur reduzierung mindestens eines symptoms für autismusspektrumserkrankungen bei einem patienten mit diagnostizierter autismusspektrumserkrankung
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
AU2010312309B2 (en) 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
EP2531589B1 (de) 2010-02-01 2017-04-05 MikrobEX Bakterientherapie für Clostridium-difficile-Colitis
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
EP2575821B1 (de) * 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Gallensäurerückflusshemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
WO2012044984A1 (en) 2010-09-30 2012-04-05 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
US9114065B2 (en) 2010-12-14 2015-08-25 Kimberly-Clark Worldwide, Inc. Method and system for monitoring nutritional uptake as a function of microflora intestinal gas levels
US20120196887A1 (en) * 2011-02-02 2012-08-02 Darkoh Charles Methods and compositions for improved rifamycin therapies
US8623914B2 (en) * 2011-02-10 2014-01-07 Tsumura & Co. Medical composition
CN103619348B (zh) 2011-04-21 2016-10-26 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
US20130017174A1 (en) * 2011-07-12 2013-01-17 The Board Of Trustees Of The University Of Arkansas Compositions and methods for increasing health and reducing pathogenic bacteria in animals
WO2013008102A2 (en) * 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2633766T3 (es) 2011-10-28 2017-09-25 Lumena Pharmaceuticals Llc Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico
US9055889B2 (en) 2012-03-20 2015-06-16 Commonwealth Laboratories, Inc. Method and apparatus for breath testing
BR112014024159A2 (pt) 2012-03-29 2017-06-20 Therabiome Llc Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
US20150050744A1 (en) * 2012-04-27 2015-02-19 Tri-X Biomedical, Inc. Diagnostic agent and diagnostic method for irritable bowel syndrome induced by abnormal proliferation of enterobacteria
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2925332A4 (de) 2012-08-20 2016-12-21 Boris Markosian Plazentale impftherapie gegen krebs
EP2895169A4 (de) * 2012-09-12 2016-02-24 Salix Pharmaceuticals Inc Verfahren zur verabreichung von rifaximin ohne erzeugung einer antibiotikaresistenz
US9702884B2 (en) 2012-09-17 2017-07-11 Cedars-Sinai Medical Center Methods for detecting the presence of irritable bowel syndrome and system for diagnosing same
JP6464142B2 (ja) 2013-03-14 2019-02-06 セラバイオーム，エルエルシー プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
AU2014239164B2 (en) 2013-03-15 2018-12-06 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
HUE040211T2 (hu) 2013-06-05 2019-02-28 Rebiotix Inc Mikrobióta-helyreállítási terápia (MRT), készítmények és elõállítási eljárások
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US20160158262A1 (en) * 2013-07-26 2016-06-09 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome
JP5719985B2 (ja) * 2013-08-01 2015-05-20 株式会社ポーラファルマ ジフェニルメチルピペラジン誘導体
PL3054977T3 (pl) 2013-10-09 2021-12-20 Cedars-Sinai Medical Center Diagnoza i leczenie zespołu jelita drażliwego i choroby zapalnej jelit
TWI505832B (zh) * 2014-02-21 2015-11-01 Genmont Biotech Inc 乳酸菌、其組合物與彼等於治療自體免疫疾病暨其倂發症之用途
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
NZ723571A (en) 2014-05-12 2020-02-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof
CN104076101A (zh) * 2014-06-13 2014-10-01 门毅 利用hplc测定尼扎替丁及注射制剂中有关物质的方法
AU2015301596B2 (en) 2014-08-13 2020-04-16 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
KR102426541B1 (ko) 2014-10-09 2022-07-29 세다르스-신나이 메디칼 센터 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
AU2015335907A1 (en) 2014-10-21 2017-04-13 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
KR20170091157A (ko) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 피린 폴리펩티드 및 면역 조정
KR101942955B1 (ko) 2014-12-23 2019-01-28 4디 파마 리서치 리미티드 면역 조정
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
JP6616431B2 (ja) 2015-06-09 2019-12-04 レビオティクス インコーポレイテッド マイクロバイオータ回復治療（ｍｒｔ）組成物の製造方法
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
ES2742514T3 (es) 2015-06-15 2020-02-14 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MX2017016529A (es) 2015-06-15 2018-03-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
AU2016278067B2 (en) 2015-06-15 2022-09-22 Cj Bioscience, Inc. Compositions comprising bacterial strains
LT3209310T (lt) 2015-11-20 2018-04-25 4D Pharma Research Limited Kompozicijos, apimančios bakterinius kamienus
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
DK3313423T3 (da) 2016-03-04 2019-05-20 4D Pharma Plc Sammensætninger omfattende bakterielle blautia-stammer til behandling af visceral hypersensitivitet
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
KR20200019882A (ko) 2017-05-22 2020-02-25 4디 파마 리서치 리미티드 세균 균주를 포함하는 조성물
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ES2823053T3 (es) 2017-06-14 2021-05-07 4D Pharma Res Ltd Composiciones que comprenden una cepa bacteriana del género Megasphaera y usos de las mismas
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
CN112400024B (zh) * 2018-06-01 2024-04-09 比奥拉治疗股份有限公司 用于胃肠道微生物组检测和处理的装置和系统
CN109055583B (zh) * 2018-08-22 2022-02-01 江南大学 一种基于细胞水平筛选通过5-羟色氨酸相关途径实现抗抑郁功能的益生菌的方法
US11763920B2 (en) 2019-07-31 2023-09-19 Dig Labs Corporation Mucus analysis for animal health assessments
BR112022001383A2 (pt) 2019-07-31 2022-03-22 Dig Labs Corp Avaliação de saúde animal
US20230077104A1 (en) * 2020-02-19 2023-03-09 The United States Government As Represented By The Department Of Veteran Affairs L-sepiapterin and methods of use for treating diseases and disorders
KR102166461B1 (ko) * 2020-03-10 2020-10-15 주식회사 종근당바이오 장관 면역조절 기능과 염증성 장 질환의 예방 또는 치료 활성을 갖는 락토바실러스 람노서스 균주
US20240010678A1 (en) * 2020-09-08 2024-01-11 The Johns Hopkins University Method of treatment of irritable bowel syndrome
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2023056419A1 (en) * 2021-09-30 2023-04-06 The General Hospital Corporation Systems and methods for assessing medical conditions such as inflammation, autoimmunity, and autism spectrum disorder (asd) and treatments thereof

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US68097A (en) * 1867-08-27 John mckenzie
US18809A (en) * 1857-12-08 Improvement in life-preservers
US152919A (en) * 1874-07-14 Improvement in clothes-driers
US124566A (en) * 1872-03-12 Improvement in combined tools
US37020A (en) * 1862-11-25 Improvement in quartz-crushers
US215421A (en) * 1879-05-13 Improvement in steam-generators
US185754A (en) * 1876-12-26 Improvement in rotary churns
US50308A (en) * 1865-10-03 James ware
US3085936A (en) * 1962-01-12 1963-04-16 S B Penick & Company Gastro-enteritis-diarrheal syndrome treatment
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
IT1090759B (it) 1977-11-29 1985-06-26 Alfa Farmaceutici Spa Procedimento per la preparazione di 3 iodio e 3 bromo rifamicina s
IT1090772B (it) 1977-12-20 1985-06-26 Alfa Farmaceutici Spa Derivati della rifamicina e procedimento per la loro preparazione
US4183960A (en) * 1978-02-01 1980-01-15 Exxon Research & Engineering Co. Detoxification by means of the controlled, in vivo secretion triggered rupture of liquid membrane capsules
JPS57500432A (de) 1980-03-20 1982-03-11
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
US4386079A (en) * 1981-11-23 1983-05-31 The Upjohn Company Method of treating depression
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4502974A (en) * 1982-03-31 1985-03-05 Chisso Corporation High temperature liquid-crystalline ester compounds
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
BE896241A (fr) * 1983-03-22 1983-07-18 Prosan Internat Composition antidiarrheique a usage veterinaire et methode d'utilisation de cette composition
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4549986A (en) 1983-12-23 1985-10-29 The Salk Institute For Biological Studies Human CGRP
FR2557453B1 (fr) * 1983-12-29 1988-02-19 Virbac Ctre Rech Biolog Nouvelle propriete pharmacocinetique des aminoglucosides
US4701457A (en) 1984-01-13 1987-10-20 Rorer Pharmaceutical Corporation Amidinoureas for treating irritable bowel syndrome
US4611011A (en) 1984-01-13 1986-09-09 William H. Rorer, Inc. Amidinoureas for treating irritable bowel syndrome
US4562188A (en) 1984-01-13 1985-12-31 William H. Rorer, Inc. Triazinones for treating irritable bowel syndrome
US4573680A (en) * 1984-03-14 1986-03-04 Mcnally James C Football training apparatus and methods of using same
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4673680A (en) 1985-09-18 1987-06-16 Pendleton Robert G α2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility
GB8525013D0 (en) * 1985-10-10 1985-11-13 Wyeth John & Brother Ltd Antidiarrhoel agents
US4990617A (en) * 1985-12-02 1991-02-05 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans and derivatives
WO1990007332A1 (en) 1986-04-25 1990-07-12 Hitoshi Shichi Immunosuppressive agent
US5869054A (en) 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5660828A (en) 1988-03-02 1997-08-26 Mayo Foundation For Medical Education & Research Method of treating autoimmune and/or viral-induced diseases that are mediated by CD8 phenotype T cells
US5236901A (en) 1988-04-20 1993-08-17 Research Corporation Technologies, Inc. Treatment for irritable bowel syndrome
US4970207A (en) 1988-07-07 1990-11-13 Fujisawa Pharmaceutical Company, Ltd. Benzodiazepine derivatives
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
GB8823203D0 (en) 1988-10-04 1988-11-09 Pfizer Ltd Therapeutic agents
US5362756A (en) * 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
FR2651581B1 (fr) 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5177069A (en) 1989-12-13 1993-01-05 Kissei Pharmaceutical Co., Ltd. Naphthysulfonylalkanoic acid compounds and pharmaceutical compositions thereof
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5120306A (en) 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
US5723218A (en) * 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5547961A (en) 1990-05-25 1996-08-20 Yamanouchi Pharmaceutical Co., Ltd. Method of treatment of intestinal diseases
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
DK0495187T3 (da) 1991-01-15 1997-08-11 Hemosphere Inc Protein-nanomatricer og fremstillingsmetode.
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US5616311A (en) 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5725804A (en) 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
US5453428A (en) 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
CA2082415A1 (en) 1991-03-07 1992-09-08 Daniel P. Becker Meso-azacyclic aromatic acid amides and esters as novel serotonergic agents
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5145869A (en) 1991-04-11 1992-09-08 Kissei Pharmaceutical Co., Ltd. Phenylsulfonylalkanoic acid compounds and pharmaceuticals thereof
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5426028A (en) 1991-07-05 1995-06-20 Rush-Presbyterian-St. Lukes Medical Center Screening method for chronic immune dysfunction syndrome
US5821259A (en) 1991-11-12 1998-10-13 Theoharides; Theoharis C. H3 -receptor agonists as therapeutic agents
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
US5811517A (en) 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
US5322697A (en) 1992-05-28 1994-06-21 Meyer James H Composition and method for inducing satiety
US5434174A (en) 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
WO1994003380A1 (en) 1992-07-31 1994-02-17 Marco Grillini Refillable liquid mixtures aerosol dispensing container
US5380522A (en) 1992-08-11 1995-01-10 Day; Charles E. Method for treatment of irritable bowel syndrome
WO1994008965A1 (en) 1992-10-16 1994-04-28 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
US5236407A (en) * 1992-11-19 1993-08-17 Lee Wang Industry Ltd. Hydraulic exerciser
US5354757A (en) * 1992-12-15 1994-10-11 G. D. Searle & Co. Azanoradamantanes
EP0674661B1 (de) 1992-12-18 2003-07-02 Molecular Rx., Inc. Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ES2196023T3 (es) 1993-01-06 2003-12-16 Kinerton Ltd Conjugados moleculares ionicos de poliesteres biodegradables y polipeptidos bioactivos.
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
HUT73494A (en) 1993-03-29 1996-08-28 Univ Cincinnati Analogs of peptide yy and uses thereof
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
ES2229045T3 (es) 1993-08-09 2005-04-16 Sod Conseils Rech Applic Derivados de peptidos terapeuticos.
JP3193205B2 (ja) 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
AU7707994A (en) 1993-09-30 1995-04-18 Tokyo Tanabe Company Limited Indoline derivative and 5-ht3 receptor antagonist containing the same as active ingredient
CA2177146C (en) 1993-11-29 1999-07-06 George Ku Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action
CA2175458C (en) 1993-11-29 1999-03-02 Boyd L. Harrison Novel benzenesulfonylimine derivatives as inhibitors of il-1 action
CA2138305A1 (en) 1993-12-28 1995-06-29 Naohito Ohashi Tumor necrosis factor production inhibitors
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
CN1099619A (zh) * 1994-03-08 1995-03-08 中国农业科学院畜牧研究所 防治猪腹泻的药物及其制备方法
US5443428A (en) * 1994-04-29 1995-08-22 April Engineering Corporation Gearless mechanical transmission
WO1995032963A1 (fr) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienylazole et compose de thienotriazolodiazepine
US5550132A (en) 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5627200A (en) 1994-09-26 1997-05-06 Pfizer Inc β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
US5834215A (en) 1994-10-05 1998-11-10 The Administrators Of The Tulane Educational Fund Method for detecting antipolymer antibodies and diagnosing silicone related disease (SRD) fibromyalgia and chronic fatigue syndrome (CFS)
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5703100A (en) 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
EP0716344A1 (de) * 1994-12-05 1996-06-12 Konica Corporation Lichtempfindliche Zusammensetzung und lithographische Druckplatte
US5599533A (en) 1994-12-15 1997-02-04 Estee Lauder, Inc. Stable water-in-oil emulsion system
US5589468A (en) 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients
US5912227A (en) 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US5691343A (en) * 1995-03-30 1997-11-25 Mayo Foundation For Medical Education And Research Use of topical azathioprine to treat inflammatory bowel disorders
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5716804A (en) * 1995-04-19 1998-02-10 Schering Corporation Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
EP0827402A2 (de) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Fettsäure enthaltende zusammensetzungen zur verbesserung der verdauung und absorption des dünndarms
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5849708A (en) * 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
US5716643A (en) 1995-06-07 1998-02-10 Hemosphere Inc. Large scale production of medicine coated crosslinked protein microspheres
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
NL1000628C2 (nl) * 1995-06-22 1996-12-24 Nederland Ptt Grondstationsysteem omvattende een eerste en een tweede grondstation, alsmede grondstation, alsmede inrichting, alsmede werkwijze.
US5846933A (en) 1996-06-28 1998-12-08 Korngold; Robert CD-4 derived peptides that inhibit immune responses
US5863529A (en) 1995-09-20 1999-01-26 Mayo Foundation For Medical Education And Research Suppression of demyelination by interleukin-6
US7081238B2 (en) * 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5716946A (en) 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US5753218A (en) 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
EP0920627B1 (de) * 1996-06-07 2004-05-12 Immunivest Corporation Magnetische trennung mit hilfe von externen und internen gradienten
US6013633A (en) 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US5861398A (en) 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
US5776524A (en) * 1996-10-30 1998-07-07 The Iams Company Process for treating small intestine bacterial overgrowth in animals
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US5830668A (en) 1996-12-13 1998-11-03 Immunosciences Lab, Inc. Detection of chronic fatigue syndrome
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US5911992A (en) 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia
US5916869A (en) * 1997-06-13 1999-06-29 North Carolina State University Method of treating birds in ovo
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
FR2769915B1 (fr) 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
US6255467B1 (en) * 1997-11-06 2001-07-03 Pathobiotek Diagnostics Inc. Human blood bacterium
US6040188A (en) * 1997-11-18 2000-03-21 The Regents Of The University Of California In vitro gastrointestinal mimetic protocol for measuring bioavailable contaminants
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
JP2002501907A (ja) 1998-01-29 2002-01-22 キナートン・リミテッド 吸収可能なマイクロ粒子の製造法
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US5968748A (en) 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
US6017879A (en) 1998-04-03 2000-01-25 B.M.R.A. Corporation B.V. Template associated NPY Y2-receptor agonists
US6013622A (en) * 1998-04-15 2000-01-11 Nutriceutical Technology Corporation Method of regulating appetite and metabolism
US6264913B1 (en) * 1998-05-08 2001-07-24 Metabolic Solutions, Inc. Non-invasive test for assessing bacterial overgrowth of the small intestine
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US6851053B1 (en) * 1999-03-02 2005-02-01 Microsoft Corporation Multiparty conference authentication
JP2000282876A (ja) * 1999-03-31 2000-10-10 Honda Motor Co Ltd ２サイクルエンジンの排気制御弁装置
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
CA2370590A1 (en) 1999-04-23 2000-11-02 Meiji Seika Kaisha, Ltd. Agent for suppressing the odors of sulfides formed through fermentation in the large intestine
US20030124566A1 (en) * 2000-02-17 2003-07-03 Kong Ning Steven 5-Hydroxytryptamine transporter gene polymorphisms
US6824988B2 (en) * 2000-05-15 2004-11-30 R.E.D. Laboratories, N.V. Method and compositions for use in diagnosing and characterizing chronic immune disease
US20020068097A1 (en) * 2000-05-19 2002-06-06 Amaresh Basu Treatment for irritable bowel syndrome and related conditions
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
AU2007201246B2 (en) 2001-04-17 2008-12-04 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
CA2453837C (en) * 2001-07-20 2011-10-04 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder using eltoprazine and related compounds
CN1596120A (zh) 2001-11-26 2005-03-16 第一三得利制药株式会社 经鼻吸收用药物组合物
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
AT501448B1 (de) 2005-03-02 2006-11-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von wässrigen ortho-phthalaldehyd-lösungen
EP1698630B1 (de) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. Neue polymorphe Formen von Rifaximin, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
WO2001011077A9 (en) 2001-09-20
US20030031625A1 (en) 2003-02-13
AU6538300A (en) 2001-03-05
US7718608B2 (en) 2010-05-18
ES2295045T3 (es) 2008-04-16
WO2001011077A3 (en) 2001-08-30
WO2001011077A2 (en) 2001-02-15
US8197805B2 (en) 2012-06-12
US20080014184A1 (en) 2008-01-17
US7585838B2 (en) 2009-09-08
EP2261665A2 (de) 2010-12-15
EP2261664B1 (de) 2015-07-01
EP2256498B1 (de) 2015-04-08
US6805852B2 (en) 2004-10-19
US7605240B2 (en) 2009-10-20
EP1811303A2 (de) 2007-07-25
EP2261665A3 (de) 2011-02-02
DE60036871T2 (de) 2008-09-18
US20110171232A1 (en) 2011-07-14
DK2256498T3 (en) 2015-05-26
ATE376673T1 (de) 2007-11-15
ATE514946T1 (de) 2011-07-15
DK1811303T3 (da) 2011-07-18
PT2256498E (pt) 2015-08-20
PT1811303E (pt) 2011-08-25
EP1200828B1 (de) 2007-10-24
US20080014185A1 (en) 2008-01-17
US7935799B2 (en) 2011-05-03
US20050008652A1 (en) 2005-01-13
US20090012113A1 (en) 2009-01-08
ES2541471T3 (es) 2015-07-20
US20090325994A1 (en) 2009-12-31
EP2261665B1 (de) 2014-06-25
US20060029550A1 (en) 2006-02-09
EP2261664A3 (de) 2011-11-02
EP1811303A3 (de) 2007-08-15
ES2366235T3 (es) 2011-10-18
US7056686B2 (en) 2006-06-06
CY1114368T1 (el) 2016-08-31
EP1811303B1 (de) 2011-06-29
EP2261664A2 (de) 2010-12-15
US6861053B1 (en) 2005-03-01
EP1200828A2 (de) 2002-05-02
EP2256498A1 (de) 2010-12-01
US7452857B2 (en) 2008-11-18

Similar Documents

Publication Publication Date Title
DE60036871D1 (de) Verfahren zur diagnose und behandlung von reizkolon-syndrom und anderen krankheiten
Attiullah et al. Clinical features of obsessive-compulsive disorder
Fombonne Prevalence of childhood disintegrative disorder
Pacella et al. Clinical and EEG studies in obsessive-compulsive states
Green et al. Effects of injury severity and cognitive exaggeration on olfactory deficits in head injury compensation claims
Mendes et al. Association of anthropometric and nutrition status indicators with hand grip strength and gait speed in older adults
Gaudreau et al. Verbal irony comprehension in older adults with amnestic mild cognitive impairment.
Cox et al. Reading proficiency affects the construct validity of the Stroop test interference score
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
Décard et al. Nerve ultrasound in miller fisher variant of Guillain–Barré syndrome
Latorre Román et al. Complex gait is related to cognitive functioning in older people: A cross-sectional study providing an innovative test
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
Gnosa et al. Impact of physical fitness on cognitive performance in patients at a memory clinic
Lincoln Discrepancies between capabilities and performance of activities of daily living in multiple sclerosis patients
Sahadevan et al. Dementia in the hospitalized elderly—a study of 100 consecutive cases in Singapore
Elkhamisi et al. Aggression dimensions in students with autism
Smeraldi et al. Testing three theories of cognitive dysfunction in alcohol abuse
Fischer et al. Recency-primacy recognition in Parkinson's disease
Gittelman Indications for the use of stimulant treatment in learning disorders
Etnier et al. Physical activity and hormone-replacement therapy: Interactive effects on cognition?
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
Binder et al. Impact of Physical Fitness on Cognitive Performance in Patients at a Memory Clinic
Zhang Too much sex, a mental disorder? Examining both sides of the debate on hypersexual disorder
Faiz Lothian Assessment for screening cognition in Aphasia (LASCA): A new non verbal assessment of cognition
Crocker et al. Inpatient Consultations of Patients with Functional GI Disorders (FGIDs) at a Tertiary Care Center: The Value of Diagnostic Testing: 1313

Legal Events

Date Code Title Description
8364 No opposition during term of opposition